{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:19:01Z","timestamp":1772767141477,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2014,8,17]],"date-time":"2014-08-17T00:00:00Z","timestamp":1408233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Most patients with advanced prostate cancer (PCa) develop bone metastases (BM) and present with bone complications like fracture. Bone\u2010targeted agents that prevent metastasis\u2010induced bone complications can cause adverse events. Understanding how patients view treatment options may optimize care. This study aimed to quantify how PCa patients value a hypothetical treatment that delays BM but can cause osteonecrosis of the jaw (ONJ). The study also assessed the value patients place on avoiding metastasis\u2010induced bone complications versus increased survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>PCa patients from the United Kingdom (n\u2009=\u2009201) and Sweden (n\u2009=\u2009200) on androgen\u2010deprivation therapy or hormone therapy for \u2265\u20093 years completed a 10\u2010question discrete\u2010choice\u2010experiment survey examining whether patients would accept a BM\u2010delaying treatment. Two time\u2010tradeoff questions assessed patients' willingness to tradeoff between survival and bone complications. Percentages of patients choosing treatment were summarized by levels of treatment efficacy and ONJ risk. Odds ratios from a logit model were used to evaluate how patient and medication characteristics affected treatment choice. Proportions of patients choosing each tradeoff scenario were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A majority of patients accepted treatment at the lowest benefit level (5\u2010month BM delay) and highest risk level (9% ONJ risk). PCa symptoms and prior treatment affected patient preferences. Nearly 80% of patients would tradeoff at least 3 months of survival to avoid bone complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>PCa patients in the UK and Sweden may value a medication that delays BM, despite the risk of ONJ. Furthermore, patients were willing to tradeoff up to 5 months of survival for prevention of bone complications. <jats:italic>Prostate 74:1488\u20131497, 2014<\/jats:italic>. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.22865","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T03:16:22Z","timestamp":1408331782000},"page":"1488-1497","source":"Crossref","is-referenced-by-count":22,"title":["Patient preferences for treatments to delay bone metastases"],"prefix":"10.1002","volume":"74","author":[{"given":"A. Brett","family":"Hauber","sequence":"first","affiliation":[{"name":"RTI Health Solutions Research Triangle Park North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Arellano","sequence":"additional","affiliation":[{"name":"Global Health Economics Amgen Inc. Thousand Oaks California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[{"name":"Global Health Economics Amgen Inc. Thousand Oaks California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Marcos","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Park North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D.","family":"Posner","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Park North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ateesha F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Park North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gatta","sequence":"additional","affiliation":[{"name":"Global Health Economics Amgen (Europe) GmbH Zug Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[{"name":"Cliniques Universitaires Saint Luc Institut de Recherche Clinique Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Jacques","family":"Body","sequence":"additional","affiliation":[{"name":"CHU Brugmann Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,17]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]","author":"Ferlay J","year":"2013"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/327253"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.2.238"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399408000616"},{"key":"e_1_2_7_6_1","first-page":"1083","article-title":"Dissemination of prostatic carcinoma: an autopsy study","volume":"78","author":"Lamothe F","year":"1986","journal-title":"J Natl Med Assoc"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6698"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23864"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0027"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.04.015"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32835ff161"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61226-9"},{"key":"e_1_2_7_14_1","unstructured":"Summary Minutes of the FDA Oncologic Drugs Advisory Committee Meeting September 14 2011. Available from:http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/ucm235829.htm Accessed on 30 January 2014."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.370"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/11539650-000000000-00000"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr559"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2012.11.007"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/11593370-000000000-00000"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecolecon.2007.02.005"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reseneeco.2010.01.006"},{"key":"e_1_2_7_23_1","volume-title":"Getting started with conjoint analysis: strategies for product design and pricing research","author":"Orme BK","year":"2006"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.6716"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/210686"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.12.35"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.22865","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.22865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T13:00:32Z","timestamp":1696510832000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.22865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,17]]},"references-count":26,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1002\/pros.22865"],"URL":"https:\/\/doi.org\/10.1002\/pros.22865","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,17]]}}}